These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010 [TBL] [Abstract][Full Text] [Related]
4. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells. van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610 [TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119 [TBL] [Abstract][Full Text] [Related]
6. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207 [TBL] [Abstract][Full Text] [Related]
7. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636 [TBL] [Abstract][Full Text] [Related]
8. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545 [TBL] [Abstract][Full Text] [Related]
9. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours. Kajtazi Y; Kaemmerer D; Sänger J; Schulz S; Lupp A J Cancer Res Clin Oncol; 2019 Oct; 145(10):2481-2493. PubMed ID: 31451931 [TBL] [Abstract][Full Text] [Related]
10. Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling. Ungefroren H; Künstner A; Busch H; Franzenburg S; Luley K; Viol F; Schrader J; Konukiewitz B; Wellner UF; Meyhöfer SM; Keck T; Marquardt JU; Lehnert H Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555512 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin and somatostatin receptors: from basic concepts to clinical applications. De Martino MC; Hofland LJ; Lamberts SW Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669 [TBL] [Abstract][Full Text] [Related]
12. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response? van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001 [TBL] [Abstract][Full Text] [Related]
13. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Cives M; Strosberg J Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185 [TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of healthcare resource utilization and costs of [ Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254 [TBL] [Abstract][Full Text] [Related]
16. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs. Cuccurullo V; Di Stasio GD; Mansi L Nucl Med Rev Cent East Eur; 2017; 20(1):49-56. PubMed ID: 28218348 [TBL] [Abstract][Full Text] [Related]
17. Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin. Mai R; Kaemmerer D; Träger T; Neubauer E; Sänger J; Baum RP; Schulz S; Lupp A Sci Rep; 2019 Mar; 9(1):4339. PubMed ID: 30867449 [TBL] [Abstract][Full Text] [Related]
18. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis. Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460 [TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A. Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P Oncology; 2019; 96(3):147-155. PubMed ID: 30282082 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study. Chicharro P; Paniagua A; Rodríguez-Jiménez P; Ibañes S; Cortina B; Riveiro J; Sampedro-Núñez MÁ; Fraga J; Marazuela M; Daudén E J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1887-1892. PubMed ID: 29377286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]